KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on Progyny to $45 from $55 to reflect his new target multiple of 4.0-times his target fiscal 2023 revenue estimate. The analyst keeps an Overweight rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PGNY: